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Novelty statement: 
 The Abbott Freestyle® Libre intermittently-viewed continuous glucose 
monitoring (iCGM) system is known to track changes in the interstitial glucose 
with sufficient accuracy compared to blood glucose in real-life conditions 
 Our data revealed significant limitations in iCGM performance during physical 
exercise in people with type 1 diabetes 
 The overall median absolute relative difference (interquartile range) was 
22%(13.9-29.7%), during hypoglycaemia 36.3%(24.2-45.2%), euglycaemia 
22.8% (14.6-30.6%) and hyperglycaemia 15.4%(9-21%)  
 From a clinical point of view iCGM can only be used as an adjunct to blood 
glucose measurements to reduce the risk of glycaemic disturbances during 
physical exercise 
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Abstract 
Aims To evaluate the sensor performance of the Abbott Freestyle® Libre intermittently-
viewed continuous glucose monitoring (iCGM) system to reference blood glucose 
levels during moderate-intensity exercise while on either full or reduced basal insulin 
dose in people with type 1 diabetes (T1DM).  
Methods Ten participants with T1DM (4 women, age 32.1±9.0 years, BMI 25.5±3.8 
kg/m2, HbA1c 55±7 mmol.mol-1 (7.2±0.6%) exercised on a cycle ergometer for 55 min 
at a moderate intensity for five consecutive days at the clinical research facility, on 
either a usual or a 75% basal insulin dose. After a four-week wash-out period, 
participants performed the second exercise period with the remaining allocation. 
During exercise reference capillary blood glucose values were analysed by fully 
enzymatic-amperometric method and compared to the referring interstitial glucose 
values. iCGM accuracy was analysed by median absolute relative difference 
(interquartile range), Clarke error grid and Bland-Altman analysis for overall glucose 
levels during exercise, stratified for glycaemic ranges and basal insulin dosing scheme 
(p<0.05).  
Results 845 glucose values were available during exercise to evaluate iCGM sensor 
performance. The overall median absolute relative difference across the glycaemic 
range was 22%(13.9-29.7%), 36.3%(24.2-45.2%) during hypoglycaemia, 22.8%(14.6-
30.6%) during euglycaemia and 15.4%(9-21%) during hyperglycaemia. A usual basal 
insulin dose was associated with a decreased sensor performance during exercise 
compared to the reduced basal insulin period (median absolute relative difference: 
23.7%(17.2-30.7%) vs. 20.5%(12-28.1%), p<0.001). 
Conclusions The iCGM sensor showed diminished accuracy during exercise. 
Absolute glucose readings derived from the iCGM sensor should be used cautiously 
and need confirmation by additional finger prick blood glucose measurements.  
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Introduction 
The Abbott Freestyle® Libre intermittently-viewed continuous glucose monitoring 
(iCGM) system is approved for monitoring glucose concentrations without the need for 
regular additional finger prick blood glucose measures. iCGM usage is not only 
convenient but with a median absolute relative difference to reference blood glucose 
levels of 11.4% in both, people with type 1 (T1DM) and type 2 diabetes the sensor has 
also shown good accuracy (1). Its regular use is associated with improved glycaemic 
control (HbA1c), lower risk of- and time spent in hypoglycaemia and less glycaemic 
variability (2).  
Regular physical activity conveys important health benefits for people with T1DM and 
exercise is advocated (3). However, the increased risk of hypoglycaemia and loss of 
glucose control discourage people with T1DM to engage in regular exercise (4). iCGM 
allows glucose measurements more frequently and is believed to help maintaining 
euglycaemia around exercise. Despite the accurate performance under real-life 
conditions little data exist on iCGM accuracy during exercise. In a previous study iCGM 
performance was evaluated around exercise and a mean ARD of 8.7±5.9% was found 
(5); however, comparison between iCGM and reference blood glucose levels were only 
available for a rather small number of measurements in this study.   
As pre-exercise bolus and/or basal insulin adjustments are regularly performed in 
people with T1DM to reduce the risk of hypoglycaemia (3) it seems to be crucial to 
investigate the impact of background insulin doses on iCGM performance, especially 
examined during repeated exercise bouts.  
This study sought to determine interstitial sensor accuracy during exercise and to 
explore the impact of alterations in background insulin on consequent interstitial 
glucose sensor accuracy during exercise in individuals with T1DM.  
 
Participants and Methods 
This study is an analysis of a prespecified secondary outcome of a clinical trial 
registered at the German Clinical Trials Register (DRKS.de; DRKS00013477). The 
primary outcome “time spent in prespecified glycaemic ranges” was recently published 
(6). The study protocol was approved by the local ethics committee (29-334 ex 16/17) 
and local health authority (EudraCT number: 2017-000922-37). The study was 
performed in a cross-over setting, including a 4-week wash out phase, having the 
participants randomised to either 100% or 75% of their basal insulin degludec. Each 
participant undertook 5 days of exercise for each dosing scheme (total of 10 days 
exercise) with 9 glucose measurements each day during the exercise sessions. 
 
Participants’ characteristics  
Details of inclusion and exclusion criteria have been described previously (6) Four 
women and six men were included in this trial with an (mean ± standard deviation (SD)) 
age of 31.4±9.0 years, body mass index (BMI) of 25.5±3.8 kg/m2, HbA1c of 55±7 
mmol.mol-1 (7.2±0.6%), diabetes duration of 19±10.9 years and a total daily insulin 
dose of 35±13 IU. 
Participants were using insulin degludec (Tresiba, Novo Nordisk A/S, DEN) as a basal 
insulin and insulin aspart (NovoRapid, Novo Nordisk A/S, DEN) as a bolus insulin for 
at least three months prior to the trial start. Participants’ maximum oxygen uptake 
(VO2max) was 39±12 mL.kg-1.min-1. 
 
Screening visit 
Participants performed a cardio-pulmonary exercise test on a cycle ergometer until 
maximal exhaustion (7). The first and the second lactate turn points as well as the 
VO2max were determined to prescribe the exercise intensity for the two exercise 
periods. Unblinded iCGM readers and sensors were provided by the study site during 
the run of the study. Participants were trained on how to use the system and seven 
participants were already using the iCGM prior to the start of the study. 
 
Trial Visits 
It was defined that the iCGM sensor must be worn for longer than 48 hours prior to the 
first exercise session. If any sensor would have been expired during the run of the trial, 
then the participants would have been told to change the sensor at least two days 
before the first exercise session to ensure sensor accuracy. During the run of the trial 
there was no case in which the participants had to change the sensor during the 5-day 
exercise period. After randomisation to either 100% or 75% of their usual basal insulin 
dose, participants exercised on a cycle ergometer for 55 min for five consecutive days 
in the evening at the clinical research facility. The moderate exercise intensity was set 
at the midpoint between the first and the second lactate turn points corresponding to 
63±7% of VO2max (6). 
Prior to the exercise sessions, participants were told to consume the last pre-exercise 
carbohydrate rich meal and inject their last bolus insulin at least two hours before the 
start of the exercise to reduce the influence of glucose fluctuations.  
If pre-exercise (-15 min) blood glucose concentration was below 7 mmol.L-1, 
participants consumed 15 to 30 g carbohydrates via fruit juice or glucose gel (8). This 
procedure was repeated if blood glucose concentration did not increase above 7 
mmol.L-1 within 10 min. In case of hypoglycaemia (3.9 mmol.L-1) exercise testing was 
discontinued and 15 to 30 g carbohydrates were administered until participants 
glucose reached 7 mmol.L-1.  
 
Measurements 
During the exercise sessions, cardio-pulmonary variables were measured 
continuously. Capillary blood samples were taken from the ear lobe immediately before 
the exercise session (resting value), after the three minute-warm-up period, every 
seven minutes during the target workload, as well as after the three minute-recovery 
period, to determine glucose concentrations as reference values by means of fully 
enzymatic-amperometric method (Biosen S-line, EKF Diagnostics, GER). The EKF 
instrument is shown to measure blood glucose accurately and can be used instead of 
the YSI system (YSI Inc., Yellow Springs, USA) (9). During exercise participants’ 
glucose concentration was measured via iCGM to obtain the accompanied interstitial 
glucose concentration. At the same timepoint of blood glucose collection from the 
earlobe a scan was performed with the iCGM reader. Interstitial glucose data were 
then transcribed from the logbook of the reader.  
 
Statistical analyses 
The primary outcome of the study was time spent in euglycaemia and based on the 
assumption that mean time in euglycaemia is increased by 10% in the 75% basal 
insulin dosing scheme, which resulted in the requirement for ten participants for the 
study to detect this difference with an alpha of 0.05 and a power of 0.90 (6). 
However, we pre-defined accuracy of interstitial glucose compared to blood glucose 
as a secondary endpoint. As for each test-to-reference measurement pair the primary 
endpoint is either success (median absolute relative difference ≤ 15%) or failure 
(median absolute relative difference > 15%), we assumed that the probability of 
success follows a binomial distribution. The appropriate statistical test to determine 
whether the probability of success meets the requirement established in the study 
hypothesis (success rate > 90%) was then a one-sample z-test of proportions. We 
expected 95% of sensor pairs to meet the criterion (effect size of 0.05). The required 
sample size with α = 0.05 and a power of 90% is therefore 359 values assessed 
during exercise testing. Our study was therefore also adequately powered for the 
analysis of this secondary outcome. iCGM sensor performance was evaluated by 
median absolute relative difference (interquartile range), Clarke error grid and Bland-
Altman analysis for overall glucose values immediate before and during exercise and 
stratified for glycaemic ranges (hypoglycaemia: ≤3.9 mmol.L-1, euglycaemia: 4.0–9.9 
mmol.L-1, hyperglycaemia: ≥10 mmol.L-1). Influence of basal insulin dose (100% vs. 
75% basal insulin dose) and the first vs. last phase of the exercise periods (first two 
days vs. last two days) on sensor performance were analysed by means of Wilcoxon 
matched-pairs signed rank test for median absolute relative difference (p<0.05).  
 
Results 
Immediately prior to the start of exercise testing, iCGM performance under resting 
condition with 90 points of comparison was found with an overall median absolute 
relative difference of 13.7% (4.7–17.3%), 14.9% (3.6–18.6%) for the 75% basal insulin 
dose and 12.4% (6.8-16.7%) for the 100% basal insulin dose. Time spent in glycaemic 
ranges given as percentage of total time was similar between 75% and 100% dosing 
scheme: hypoglycaemia 3 ± 2% vs. 4 ± 2%, euglycaemia 77 ± 16% vs. 81 ± 15% and 
hyperglycaemia 20 ± 13% vs. 15 ± 7% (p > 0.05). In total we observed 7 hypoglycaemic 
episodes in 6 participants, 3 in the 100% dosing scheme and 4 in the 75% dosing 
scheme that were treated each with 24 ± 9 g liquid glucose during the exercise 
sessions. The rate of change in glucose for the entire observational period was found 
at 0.054 mmol.L-1.min-1, 0.051 mmol.L-1.min-1 for 100% basal insulin dose and 0.057 
mmol.L-1.min-1 for the 75% basal insulin dose. Overall, 57% of blood glucose levels 
showed a rate of change of below 0.1 mmol.L-1.min-1 and 36% showed a rate of change 
of below 0.06 mmol.L-1.min-1. For blood glucose measured by the EKF system we 
found an inter-individual coefficient of variation of 34% and an intra-individual 
coefficient of variation of 33% during exercise testing. iCGM measured glucose 
revealed an inter-individual coefficient of variation of 32% and an intra-individual 
coefficient of variation of 31% during exercise testing. 
Out of potentially 900 points of comparisons, 845 points were available as the iCGM 
did not display values in 10 cases (1%) and one participant did not perform the second 
exercise period due to personal reasons. Carbohydrate intake per participant per 
exercise session was similar for the full basal insulin dose (100%) in comparison to the 
reduced basal insulin dose (75%) during exercise (36(9–66 g) vs. 36(9–62 g), p=0.78).  
Bland-Altman analysis and Clarke error grids for the overall glycaemic range during 
exercise, as well as Clarke error grids zone percentages and median absolute relative 
difference at different levels of glycaemia (hypo-, eu- and hyperglycaemia) are 
presented in table1 (Bland-Altman and Clarke error grids) and figure 1 (Clarke error 
grids). 
Overall the median absolute relative difference across the glycaemic range during 
exercise was 22%(13.9–29.7%), during exercise-induced hypoglycaemia 36.3%(24.4–
45.2%), during euglycaemia 22.8%(14.6–30.6%) and in periods of hyperglycaemia 
15.4%(9-21%). Continuation of the full basal insulin dose during the exercise week was 
associated with impaired sensor performance in comparison to a reduced basal insulin 
dose (75%) (median absolute relative difference: 23.7%(17.2–30.7%) vs. 20.5%(12–
28.1%), p<0.001) despite similar mean blood glucose concentrations (7.4±2.4 mmol.L-
1 vs. 7.5±3.0 mmol.L-1, p=0.73) and similar blood glucose decreases (ΔBGstart-end exercise: 
2.82±0.59 mmol.L-1 vs. 3.13±0.42 mmol.L-1, p=0.19) . 
Bland-Altman analysis revealed that the iCGM system reported higher glucose levels 
than the reference capillary blood glucose concentration (bias 1.95, 95% limits of 
agreement from -0.98 to 4.89 mmol.L-1). A reduction in basal insulin dose (75% basal 
dose) during the exercise week resulted in numerically less bias and limits of 
agreements as compared to continuation of the full basal insulin dose (1.69, -1.28 to 
4.67 mmol.L-1 vs. 2.24, -0.56 to 5.05 mmol.L-1). 
The overall clinical performance analysed via Clarke error grids was found at 76% of 
values in zone A, 22% in zone B and 2% in zone D, with similar results when data were 
stratified for basal insulin dose (Figure 1). 
The analysis of the first vs. the last exercise period on iCGM performance (median 
absolute relative difference) resulted in a decrease of accuracy in the full basal insulin 
dose (p=0.01) but not for the 75% basal insulin dose (p=0.15).  
 
Discussion 
This study revealed that the accuracy of the iCGM system measured glucose was 
distinctively reduced compared to capillary glucose during moderate-intensity exercise. 
This is a significant finding given the fact that blood glucose was kept within a well-
controlled range without large decreases in blood glucose during exercise due to small 
amounts of exogenous carbohydrate intake. Where glucose concentrations fell to 
hypoglycaemic levels a median absolute relative difference of 36.3%(24.2–45.2%) 
strongly suggests that this device should only be used as an adjunct to blood glucose 
measurements during exercise. Additionally, early acting on trend arrows provided by 
the system can be used as a supportive tool to reduce the risk of exercise-induced 
hypoglycaemia. 
An overestimation of iCGM values in comparison to blood glucose reference values 
was demonstrated by Bland-Altman analysis and this overestimation might increase 
potential for wrong therapeutic decisions. Our results are in contrast with findings from 
a previous work of our research team that evaluated the iCGM system to be accurate 
during exercise testing with a mean ARD of 8.7±5.9% and a Parks error grid of 100% 
of values in zone A (5). These differences in findings might be based on the low number 
of comparison points (n=13) and the short duration of exercise (2x15 minutes) 
performed in the previous study. One could speculate that exercise induced changes 
in subcutaneous blood flow and larger glucose swings during exercise might at least 
partly explain the higher median absolute relative difference compared to non-exercise 
studies. 
In our analysis the basal insulin dose was associated with iCGM performance during 
exercise. A regular basal insulin dose was associated with a decrease in sensor 
accuracy.  
Interestingly, when comparing the devices’ performance by means of the continuum of 
exercise tests (first exercise phase vs. last exercise phase) only for the regular basal 
insulin dose the accuracy decreased. Whether those associations are reproducible or 
just a play of chance remains to be elucidated. 
The physiological response to higher circulating insulin levels combined with exercise 
might impact the dynamics of blood glucose changes, with subsequent increasing 
discrepancy between blood and interstitial glucose values. To overcome this lag time 
and to reduce the risk of inadequate therapy decisions, an exercise-related algorithm 
could improve sensor performance (10). However, a recent study in people with T1DM 
running on continuous subcutaneous insulin infusion showed that a 50% reduction in 
basal rate 1 hour prior to the start of exercise testing did not significantly reduce free 
circulating insulin during exercise (11). As shown previously the sensor performance 
is depending on the rate of change in glucose concentration (12). Under stable 
conditions and under rates of change between -0.05 to 0.05 mmol.L-1.min-1 sensor 
performance revealed a median absolute relative difference of 8.5%. In our study the 
rate of change can be interpreted as less influential on the results since the rate of 
change was found at 0.051 mmol.L-1.min-1 for 100% basal insulin dose and 0.057 
mmol.L-1.min-1 for 75% basal insulin dose. 
Our study is limited since we did not standardise the timepoint of the last pre-exercise 
bolus insulin injection that might have influenced sensor performance due to the 
combination of the insulin sensitising effect of exercise and bolus insulin action. 
Additionally, despite being shown that blood glucose collected from earlobe in 
comparison to fingertip did not result in clinically relevant differences under resting 
conditions (13), a bias of sampling sites might be existing especially during exercise 
(14). Direct comparability of different blood glucose collection sites is therefore 
challenging.  
Although previous research found that the iCGM system is accurate during real life 
conditions and improve glycaemic control (1,2,5,15), during exercise the accuracy for 
absolute glucose values measured is only moderate and additional finger prick glucose 
measurements are required. In comparison to a previous study performing exercise 
with a similar mean exercise intensity using the Medtronic Enlite™ sensor (Medtronic 
Diabetes, USA) the mean absolute relative difference was found at 12.8% (16). 
However, trend arrows of iCGM providing information about velocity of glucose 
changes could still be of value during exercise.  
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Table 1 Median absolute relative difference (interquartile range) and Bland-Altmann 
analysis during exercise. Median absolute relative difference is defined as [(sensor 
glucose – reference blood glucose) ⁄ reference blood glucose] expressed as a 
percentage. Median absolute relative difference indicates absolute values of difference 
and thus ignores the direction of the measurement error but indicate the size of the 
error expressed as percentage error. 
 


























Overall 22.0% (13.9 – 29.7%) 
(n = 845) 
Hypoglycaemia (≤ 3.9 mmol.L-1) 36.3% (24.2 – 45.2%) 
(n = 30) 
Euglycaemia (4.0 – 9.9 mmol.L-1) 22.8% (14.6 – 30.6%) 
(n = 668) 
Hyperglycaemia (≥ 10 mmol.L-1) 15.4% (9 - 21%) 
(n = 147) 
100% basal insulin dose (19 ± 4 IU) 23.7% (17.2 – 30.7%) 
(n = 400) 
75% basal insulin dose (14 ± 3 IU) 20.5% (12 – 28.1%) 
(n = 445) 
First exercise period 100% basal 
insulin dose (19 ± 4 IU) 
22.1% (17.2 – 29.2%) 
(n = 138) 
Last exercise period 100% basal 
insulin dose (19 ± 4 IU) 
24.9% (16.1 - 33%) 
(n = 142) 
First exercise period 75% basal insulin 
dose (14 ± 3 IU) 
20.4% (11.7 – 28.2%) 
(n = 180) 
Last exercise period 75% basal 
insulin dose (14 ± 3 IU) 
20.4% (13 – 27.1%) 












1.95 (-0.99 – 4.89 mmol.L-1) 
(n = 845) 
100% basal insulin dose (19 ± 4 IU) 
2.24 (-0.56 – 5.05 mmol.L-1) 
(n = 400) 
75% basal insulin dose (14 ± 3 IU) 
1.69 (-1.28 – 4.67 mmol.L-1) 
(n = 445) 
 
  
Figure 1 Clarke error grids for overall- (A), 100% basal insulin dose- (B) and 75% basal 
insulin dose-glucose values (C). The x-axis displays reference blood glucose values 
(mmol.L-1), the y-axis presents the values measured by the iCGM system (mmol.L-1). 
The grid is divided into zones showing the degree of risk caused by erroneous 
measurements: zone A means no effect on clinical action; zone B represents altered 
clinical action—small or no significant effect on clinical outcome; zone C represents 
altered clinical action— probable to affect clinical outcome; zone D means altered 
clinical action—could have significant medical risk; and zone E represents altered 





Supporting information 1 Mean and SD blood glucose and iCGM glucose 
responses to the exercise session for (A) 100% basal insulin dose and (B) 75% basal 
insulin dose.  
 
Supporting information 2 Bland–Altman plots for (A) overall exercise sessions, (B) 
100% basal insulin dose and (C) 75% basal insulin dose. The x-axis represents the 
average of blood glucose reference and iCGM values, the y-axis represents the 
difference (iCGM – blood glucose). The long-dashed lines indicate bias and the 95% 
limits of agreement.  
